The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the ...

Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

After opening the year projecting COVID vaccine sales of between $800 million and $1 billion, Novavax has slashed its estimate to a range of $275 million to $375 billion. (Photo by Patrick van Katwijk ...

Novavax has brought together its coronavirus vaccine with its expertise in flu to create a candidate that would protect people from both flu and COVID for the season. This could be particularly ...

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with ...